96 related articles for article (PubMed ID: 2565205)
1. On the antipyrine test in laboratory animals. Studies in the dog and monkey.
Vickers FF; Bowman TA; Dvorchik BH; Passananti GT; Hughes DM; Vesell ES
Drug Metab Dispos; 1989; 17(2):160-5. PubMed ID: 2565205
[TBL] [Abstract][Full Text] [Related]
2. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
3. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch RA; Shand DG; Wilkinson GR; Nies AS
J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
[TBL] [Abstract][Full Text] [Related]
4. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.
Shukla UA; Marathe PH; Pittman KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):502-7. PubMed ID: 8100508
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
7. Phencyclidine (PCP) disposition kinetics in dogs as a function of dose and route of administration.
Woodworth JR; Owens SM; Mayersohn M
J Pharmacol Exp Ther; 1985 Sep; 234(3):654-61. PubMed ID: 4032285
[TBL] [Abstract][Full Text] [Related]
8. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling.
Feng MR; Loo J; Wright J
Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
Groen K; Breimer DD; van Bezooijen CF
Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.
van der Graaff M; Vermeulen NP; Joeres RP; Vlietstra T; Breimer DD
J Pharmacol Exp Ther; 1983 Nov; 227(2):459-65. PubMed ID: 6631725
[TBL] [Abstract][Full Text] [Related]
11. Antipyrine pharmacokinetics and urinary excretion in female horses.
Dyke TM; Sams RA; Hinchcliff KW
Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
14. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
15. Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals.
Schillings RT; Sisenwine SF
Drug Metab Dispos; 1986; 14(4):405-12. PubMed ID: 2873986
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
[TBL] [Abstract][Full Text] [Related]
17. Disposition of remoxipride in different species. Species differences in metabolism.
Widman M; Nilsson LB; Bryske B; Lundström J
Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine.
Ahr HJ; Krause HP; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Aug; 38(8):1093-8. PubMed ID: 3196402
[TBL] [Abstract][Full Text] [Related]
19. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
20. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
